Zydus Lifesciences Gets USFDA Nod for Ammonium Lactate Cream

Zydus Lifesciences Limited has secured final approval from the USFDA for Ammonium Lactate Cream, 12%. This cream is a topical medication used to treat dry, scaly skin (xerosis) and the genetic condition ichthyosis vulgaris.

It functions by hydrating the skin, increasing its moisture content and decongesting itchiness. Being an alpha-hydroxy acid, it also makes the skin soft and lessens scaling of the skin.

The cream shall be manufactured in Zydus, Changodar, Ahmedabad plant and shall be sold in the United States under the Viona Pharmaceuticals Inc. banner. The data provided by IQVIA showed that by December 2025, Ammonium Lactate Cream had an annual market of USD 15 million in the U. S.

Also Read: Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts

Through this approval Zydus has achieved an important milestone as it has 430 approvals and 505 ANDAs have been filed since FY 2003-04. The further development of the company is the determination to deliver effective and high quality treatment to the patients in the world.

The recent success of Zydus confirms its role in the pharmaceutical industry worldwide and reflects its continued commitment to the betterment of the life of people with chronic skin diseases.